Clinical Trials in La Rochelle, France
1 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled300 locationsNCT06692738
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 4
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
GFPC Investigation500 enrolled41 locationsNCT06646471
Recruiting
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancer
GFPC Investigation1,000 enrolled46 locationsNCT07243132
Recruiting
Not Applicable
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Metastatic Triple-Negative Breast Carcinoma
UNICANCER472 enrolled51 locationsNCT06505018
Recruiting
Not Applicable
Program of Physical Activity, Nutrition and Supportive to Improve the Quality of Life of Breast Cancer Survivors
Breast CancerQuality of Life
Siel Bleu160 enrolled8 locationsNCT05658341
Recruiting
Phase 3
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Metastatic Non-squamous Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris1,166 enrolled37 locationsNCT05692999